Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorChina National Center for Cardiovascular Diseases
About this trial
Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.
Eligibility criteria
Qualifiers
Adult patients with diffuse coronary artery disease undergoing CE+CABG during the study period.
No contraindications for both dual antiplatelet therapy and anticoagulation therapy with warfarin.
Must be able to swallow tablets after the surgery.
Disqualifiers
Patients with high bleeding risk (HAS-BLED ≥ 3);
Patients undergoing concomitant aortic valve or mitral valve surgery, or undergoing cardiac surgery for the second time;
Emergency surgery;
Serum creatinine >130μmol/L, or significant liver dysfunction (elevated ALT and/or AST);
Trial design
Treatments tested in this trial
- Warfarin
- DAPT
- CE+CABG
Treatment groups
202 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov